In short
SODIUM BITUMINOSULFONATE DRY SUBSTANCE is being studied in clinical trials for people with active mild to moderate hidradenitis suppurativa. These trials look at whether it can help improve disease signs and how well it works compared with placebo. The main focus is on efficacy and trial outcomes in adult patients.
Key points
- SODIUM BITUMINOSULFONATE DRY SUBSTANCE is being studied in a completed Phase 2 trial for active mild to moderate hidradenitis suppurativa. The study tested a first-line treatment approach and compared the drug with placebo in a randomized, double-blind design. A total of 186 participants were enrolled. The main outcome was HiSCR50 at week 6, which checks for meaningful improvement in disease signs. This trial focused on whether a 6-week treatment course could improve symptoms in people with this skin condition.
Trial overview
The available trial studied SODIUM BITUMINOSULFONATE DRY SUBSTANCE in people with active mild to moderate hidradenitis suppurativa.
This was a completed Phase 2 study, which means it was designed to look at early signs of benefit in a patient group while still checking how the treatment performs in a controlled setting.
The study title described it as a randomized, double-blind, placebo-controlled trial of IC0624 as first-line therapy.
Study design and treatment groups
The trial was interventional, meaning researchers assigned a treatment rather than only observing patients.
It was randomized, so participants were placed into study groups by chance.
It was also double-blind, which means neither the participants nor the study team knew who received the active treatment or the placebo during the study.
The comparison group received a placebo, which is an inactive treatment used to help show whether the study drug has an effect beyond expectation alone.
The brief study summary said the goal was to evaluate the clinical efficacy of a 6-week intake of IC0624.
Who could participate
The study focused on patients with active mild to moderate hidradenitis suppurativa.
This means the trial was not for people with quiet disease; it was for those who still had active symptoms at the time of enrollment.
The study was described as first-line therapy, so it was aimed at people who might be using this treatment as an early treatment option for their condition.
A total of 186 participants were enrolled.
What the study measured
The main outcome, or primary endpoint, was HiSCR50 at week 6.
HiSCR50 is a study measure used in hidradenitis suppurativa to show whether there was at least a 50% improvement in disease signs.
Week 6 means the outcome was checked after six weeks of treatment.
The study summary also stated that the trial was designed to evaluate the clinical efficacy of a 6-week intake of IC0624.
What the trial means for patients
For patients, this trial shows that SODIUM BITUMINOSULFONATE DRY SUBSTANCE was tested in a controlled study for a painful chronic skin condition, not just in routine care.
The use of placebo and blinding makes the study more reliable because it helps reduce bias, which is when results are influenced by expectations rather than the treatment itself.
The main question was simple: can a 6-week course improve the signs of hidradenitis suppurativa in people with active mild to moderate disease?
Because the trial is completed, the key design details are known, but the provided source does not include full outcome results beyond the planned primary endpoint.